Back to search results

Evaluate the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa.

Abroad (travel likely)RecruitingEARLY_PHASE1

Conditions

Hidradenitis Suppurativa

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • University of Alabama at Birmingham, Birmingham, Alabama, United States

    Contact: Study coordinator (Ralee' B Bunt, MSPH) · erikabunt@uabmc.edu · 205-975-1034
    Contact: Principal Investigator (Tiffany Mayo, MD)
Study leads

  • Tiffany Mayo, MD

    Principal Investigator

    University of Alabama at Birmingham

View source on ClinicalTrials.gov(opens in a new tab)